Linda Pestano
About Linda Pestano
Linda Pestano is the Chief Development Officer with expertise in designing pre-clinical programs for cancer and inflammatory diseases. She holds a PhD in Immunology from Tufts and completed postdoctoral research at Dana Farber, Harvard Medical School.
Linda Pestano, Chief Development Officer
Linda Pestano serves as the Chief Development Officer. In this role, she is responsible for overseeing the development and implementation of strategic programs and initiatives aimed at advancing the company’s mission. Her leadership and expertise drive the development of pre-clinical programs focused on building investigational new drug (IND)-enabling data packages for lead candidate compounds. These compounds are targeted for the treatment and diagnosis of cancer and inflammatory diseases.
Linda Pestano's Education and Expertise
Linda Pestano earned her PhD in Immunology from Tufts. This advanced degree equipped her with a deep understanding of the immune system and its applications in medicine. Her focus on immunology plays a critical role in her current work, where she designs pre-clinical programs to build IND-enabling data packages for candidate compounds. Her academic background reinforces her proficiency in both the development and implementation of innovative medical solutions.
Linda Pestano's Postdoctoral Research
Linda Pestano conducted her postdoctoral research at Dana Farber in affiliation with Harvard Medical School. During her tenure, she gained extensive experience in cutting-edge research methodologies and deepened her expertise in cancer and inflammatory diseases. This period of research fostered a profound understanding of disease mechanisms and advanced Linda's capabilities in designing effective therapeutic and diagnostic strategies.
Linda Pestano's Focus on Cancer and Inflammatory Diseases
Linda Pestano has substantial experience in designing pre-clinical programs aimed at creating IND-enabling data for lead candidate compounds. These compounds are intended for the treatment and diagnosis of cancer and inflammatory diseases. Her work involves creating comprehensive data packages that facilitate the progression of new therapeutic compounds from pre-clinical stages to clinical trials, ultimately contributing to the development of new treatments.